Last reviewed · How we verify

Express Specialty Pharmacy — Portfolio Competitive Intelligence Brief

Express Specialty Pharmacy pipeline: 1 marketed, 0 filed, 0 Phase 3, 12 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 12 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Prilocaine 2.5% Prilocaine 2.5% marketed Local anesthetic (amide) Voltage-gated sodium channels Anesthesia

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Nantes University Hospital · 3 shared drug classes
  2. Oslo University Hospital · 2 shared drug classes
  3. Bozyaka Training and Research Hospital · 2 shared drug classes
  4. Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias · 2 shared drug classes
  5. Keimyung University Dongsan Medical Center · 2 shared drug classes
  6. Kasr El Aini Hospital · 2 shared drug classes
  7. Beijing Tiantan Hospital · 2 shared drug classes
  8. Pontificia Universidad Catolica de Chile · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Express Specialty Pharmacy:

Cite this brief

Drug Landscape (2026). Express Specialty Pharmacy — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/express-specialty-pharmacy. Accessed 2026-05-14.

Related